Biofrontera Inc. (BFRI)
NASDAQ: BFRI · Real-Time Price · USD
0.7188
+0.0363 (5.32%)
At close: May 13, 2025, 4:00 PM
0.7671
+0.0483 (6.72%)
Pre-market: May 14, 2025, 5:16 AM EDT
Biofrontera Revenue
In the year 2024, Biofrontera had annual revenue of $37.32M with 9.54% growth. Biofrontera had revenue of $12.56M in the quarter ending December 31, 2024, with 18.53% growth.
Revenue (ttm)
$37.32M
Revenue Growth
+9.54%
P/S Ratio
0.11
Revenue / Employee
$401,301
Employees
93
Market Cap
6.38M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
BFRI News
- 7 days ago - Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025 - Accesswire
- 12 days ago - Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis - GlobeNewsWire
- 7 weeks ago - Biofrontera Inc. (BFRI) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update - GlobeNewsWire
- 2 months ago - Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk - GlobeNewsWire
- 2 months ago - Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025 - GlobeNewsWire
- 4 months ago - Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - GlobeNewsWire
- 5 months ago - Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market - GlobeNewsWire